Exelixis
EXEL
#1673
Rank
โ‚ฌ9.45 B
Marketcap
33,10ย โ‚ฌ
Share price
-0.54%
Change (1 day)
68.47%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of September 2024 : โ‚ฌ1.12 Billion

According to Exelixis's latest financial reports the company has โ‚ฌ1.12 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31โ‚ฌ0.90 B-26.19%
2022-12-31โ‚ฌ1.21 B-5.84%
2021-12-31โ‚ฌ1.29 B32.06%
2020-12-31โ‚ฌ0.98 B28.94%
2019-12-31โ‚ฌ0.76 B25.53%
2018-12-31โ‚ฌ0.60 B87.53%
2017-12-31โ‚ฌ0.32 B-19.02%
2016-12-31โ‚ฌ0.39 B161.21%
2015-12-31โ‚ฌ0.15 B28.79%
2014-12-31โ‚ฌ0.11 B-32.43%
2013-12-31โ‚ฌ0.17 B-43.56%
2012-12-31โ‚ฌ0.31 B107.93%
2011-12-31โ‚ฌ0.14 B22.32%
2010-12-31โ‚ฌ0.12 B-13.73%
2009-12-31โ‚ฌ0.14 B-24.48%
2008-12-31โ‚ฌ0.18 B0.93%
2007-12-31โ‚ฌ0.18 B37.18%
2006-12-31โ‚ฌ0.13 B8.05%
2005-12-31โ‚ฌ0.12 B9.68%
2004-12-31โ‚ฌ0.11 B-39.25%
2003-12-31โ‚ฌ0.18 B-11.32%
2002-12-31โ‚ฌ0.21 B-17.64%
2001-12-31โ‚ฌ0.25 B115.8%
2000-12-31โ‚ฌ0.11 B1642.38%
1999-12-31โ‚ฌ6.85 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
โ‚ฌ4.08 B 261.49%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ6.91 B 512.54%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ13.85 B 1,127.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ7.68 B 580.65%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ8.55 B 657.76%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ19.26 B 1,606.84%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ9.44 B 736.89%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ26.92 M-97.62%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ73.48 M-93.49%๐Ÿ‡บ๐Ÿ‡ธ USA